FATE THERAPEUTICS INC (FATE) Debt Components
- 2019-09-30: Convertible Notes Payable, CurrentUSD (m); Long-term Debt, Current MaturitiesUSD $13.93M; Long-term Debt, Excluding Current MaturitiesUSD (m); Convertible Notes PayableUSD (m).
- 2019-06-30: Convertible Notes Payable, CurrentUSD (m); Long-term Debt, Current MaturitiesUSD $5.45M; Long-term Debt, Excluding Current MaturitiesUSD $9.47M; Convertible Notes PayableUSD (m).
- 2019-03-31: Convertible Notes Payable, CurrentUSD (m); Long-term Debt, Current MaturitiesUSD $3.94M; Long-term Debt, Excluding Current MaturitiesUSD $10.96M; Convertible Notes PayableUSD (m).
- 2018-12-31: Convertible Notes Payable, CurrentUSD (m); Long-term Debt, Current MaturitiesUSD $2.44M; Long-term Debt, Excluding Current MaturitiesUSD $12.45M; Convertible Notes PayableUSD (m).
FATE THERAPEUTICS INC Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Convertible Notes Payable, Current USD | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Convertible Notes Payable USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-term Debt, Gross USD | Debt Instrument, Face Amount USD | Debt Instrument, Convertible, Beneficial Conversion Feature USD | Debt Instrument, Unamortized Discount USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019-09-30 | (m) | $13.93M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $14.00M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $5.45M | $9.47M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $15.00M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $3.94M | $10.96M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $15.00M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $2.44M | $12.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $15.00M | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | $18.48M | $3.72M | $6.82M | $6.31M | $1.63M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $3.26M | $11.60M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $15.00M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $2.01M | $12.84M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $15.00M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $758.00K | $14.07M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $15.00M | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | $14.81M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $15.00M | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | $19.32M | $1.22M | $5.64M | $5.66M | $5.25M | $1.54M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | $14.79M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $15.00M | (m) | (m) | (m) |
| 2017-07-14 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $15.00M | (m) | (m) |
| 2017-06-30 | (m) | (m) | $6.68M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $6.71M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $7.62M | $1.08M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $8.75M | (m) | (m) | (m) |
| 2016-12-31 | (m) | $8.19M | $2.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $10.77M | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | $12.81M | $8.76M | $4.05M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $8.03M | $4.61M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $12.74M | (m) | (m) | (m) |
| 2016-06-30 | (m) | $7.86M | $6.68M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $14.68M | (m) | (m) | (m) |
| 2016-03-31 | (m) | $7.71M | $8.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $16.58M | (m) | (m) | (m) |
| 2015-12-31 | (m) | $7.55M | $10.69M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $18.45M | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | $21.57M | $8.76M | $8.76M | $4.05M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $6.49M | $12.63M | (m) | $19.28M | (m) | (m) | (m) | (m) | (m) | $19.39M | (m) | (m) | (m) |
| 2015-06-30 | (m) | $5.16M | $14.54M | (m) | $19.86M | (m) | (m) | (m) | (m) | (m) | $20.00M | (m) | (m) | (m) |
| 2015-03-31 | (m) | $3.26M | $16.41M | (m) | $19.83M | (m) | (m) | (m) | (m) | (m) | $20.00M | (m) | (m) | (m) |
| 2014-12-31 | (m) | $1.53M | $18.07M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $20.00M | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | $19.62M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | $2.90M | $8.76M | $8.76M | $4.05M | (m) | (m) | (m) | (m) | $-371.00K |
| 2014-09-30 | (m) | $611.00K | $9.39M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $10.00M | (m) | (m) | (m) |
| 2014-06-30 | (m) | $746.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $750.00K | (m) | (m) | (m) |
| 2014-03-31 | (m) | $1.24M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.25M | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $336.00K | (m) |
| 2013-12-31 | (m) | $1.73M | (m) | (m) | $1.75M | (m) | (m) | (m) | (m) | (m) | $1.75M | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 80 month · $336.00K | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | $2.01M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-10-04 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $300.00K |
| 2013-09-30 | $3.48M | $1.97M | $250.00K | $23.70M | $2.25M | (m) | (m) | (m) | (m) | (m) | $2.25M | (m) | (m) | (m) |
| 2012-12-31 | (m) | $1.94M | $1.73M | (m) | $3.73M | (m) | (m) | (m) | (m) | (m) | $3.75M | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |